Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06082492Recruiting
PET/CT scans for follow-up of stage III lung cancer
This trial is testing whether adding a PET/CT scan to routine follow-up care helps patients with stage III non-small cell lung cancer. It aims to see if this extra imaging can detect any return of cancer earlier, which may help with treatment decisions.
Hilversum, UtrechtAges 18 years+ - NCT06084078Recruiting
Rural Illinois lung cancer screening study
This study aims to improve lung cancer screening for people in rural Illinois who have a history of heavy smoking. It tests a program to help more people get screened and catch cancer early.
Springfield, IllinoisAges 50–80 - NCT06087692Recruiting
Video game therapy for lung disease patients
This trial tests whether playing interactive video games can help people with interstitial lung disease (a type of chronic lung condition). It aims to improve breathing and daily function through fun, guided exercises.
IstanbulAges 40–65 - NCT06095505RecruitingPhase 2
Alisertib for extensive stage small cell lung cancer
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
Daphne, AlabamaAges 18 years+ - NCT06105177Recruiting
Using blood tests to guide lung cancer care
This trial uses a simple blood test (liquid biopsy) to find tumor DNA in people suspected of having lung cancer. The goal is to learn if this test can help doctors make better treatment decisions without needing a tissue sample.
Heerlen, LimburgAges 18 years+ - NCT06109454Recruiting
Huaier granules after lung cancer surgery
This study tests whether Huaier granules can help prevent lung cancer from coming back after surgery. It is for people with stage II–IIIA non-small cell lung cancer who have recently had their tumor completely removed and have not had other treatments like chemotherapy or radiation.
Shenyang, LiaoningAges 18–75 - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT06110572RecruitingPhase 1/Phase 2
Total body irradiation with immunotherapy for extensive SCLC
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT06116786RecruitingPhase 1
Experimental drug JNJ-86974680 for advanced lung cancer
This study tests an experimental drug called JNJ-86974680 for people with advanced non-small cell lung cancer. It looks at how well the drug works, whether you have a gene change or not, and what treatments you've already had.
Newnan, GeorgiaAges 18 years+ - NCT06122077Recruiting
Blood test for early lung cancer detection in smokers
This trial tests a blood test that looks for multiple signals to find lung cancer early. If you are a smoker or former smoker over 50, this test might help detect cancer before you have symptoms.
Los Angeles, CaliforniaAges 50 years+ - NCT06122233Recruiting
Digital self-management for fibrotic lung disease
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Sydney, New South WalesAges 18 years+ - NCT06128837RecruitingPhase 3
Study of a new drug for recurrent small cell lung cancer
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
BeijingAges 18 years+ - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT06147570RecruitingPhase 2
Study of HS-10365 for RET fusion-positive lung cancer
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06159660Recruiting
Lung Imaging to Reduce Radiation Side Effects
This trial tests a new way to plan radiation therapy for lung cancer by using a special imaging technique (functional lung imaging) to see which parts of your lungs work best. The goal is to reduce damage to healthy lung tissue while still targeting the cancer.
St Leonards, New South WalesAges 18 years+ - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06180005Recruiting
Lung cancer genetic drivers study at CRO Aviano
This study is looking at people with non-small cell lung cancer (NSCLC) to find certain genetic changes that drive the cancer. It may help doctors understand which treatments could work best for you.
Aviano, PordenoneAges Any age - NCT06181357Recruiting
Comparing one-step vs. two-step valve placement for severe emphysema
This trial tests whether placing ZEPHYR® valves in two stages reduces the risk of a collapsed lung (pneumothorax) compared to the usual one-stage procedure. It is for people with severe emphysema who have already quit smoking and meet specific lung function criteria.
BordeauxAges 35–80 - NCT06181812Recruiting
Genetic testing for lung adenocarcinoma
This study looks at inherited genetic changes in people with a type of lung cancer called lung adenocarcinoma. The goal is to find gene variants linked to the disease, which may help guide future treatment decisions.
Mexico City, Mexico CityAges 16–85 - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06196008Recruiting
Exercise coaching for older adults having lung cancer surgery and their caregivers
This study tests if a telephone-based physical activity coach helps older adults (65+) recover better after lung cancer surgery compared to self-monitored activity. Caregivers can also join to learn how to support their loved one and improve their own well-being.
Davis, CaliforniaAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,885 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.